OR WAIT 15 SECS
BioCity has invested in Maxwellia, a company based at Alderley Park in the United Kingdom that is driving industry movement towards self-care therapeutics.
Life-science incubator and business collective, BioCity, has invested in Maxwellia, a company based at Alderley Park in the United Kingdom that is driving industry movement towards self-care therapeutics.
Maxwellia’s success at securing funding from BioCity is thanks to its novel approach to converting prescription drugs to over-the-counter (OTC) versions, ultimately enabling faster patient access to therapies without the need for a doctor’s appointment. With the investment, Maxwellia will advance three products within women’s health and healthy lifestyle, two of which are already undergoing approval with the Medicines and Healthcare products Regulatory Agency.
“Maxwellia are spearheading the move towards self-care therapeutics, their potential impact is vast,” said Imelda Juniarsih, BioCity investment analyst, in a Sep. 3, 2019 press release. “By providing consumers with quicker, wider, and more convenient access to medicines and reducing the burden felt by the NHS [National Health Service], Maxwellia could support and accelerate the move towards self-care and provide early intervention opportunities for some long-term conditions in the UK. The Maxwellia team, led by Anna Maxwell, have both the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.”
Anna Maxwell, Maxwellia CEO and founder, commented, “We are delighted to have the support of the BioCity fund and the benefits of their mentorship in this important phase of Maxwellia’s journey towards the commercialization of our first approved product.”